Home / Therapies / Blood Glucose Control / Retatrutide vs. Ozempic: What the 80-Week Head-to-Head Diabetes Trial Revealed

Retatrutide vs. Ozempic: What the 80-Week Head-to-Head Diabetes Trial Revealed

Nov 14, 2026
7,998 views
 

New clinical trial results offer a closer look at how retatrutide compares with semaglutide for treating type 2 diabetes. On October 28, 2026, Eli Lilly reported greater A1C reductions and weight loss with investigational retatrutide than with Ozempic 2 mg. However, these findings come from a company announcement rather than a fully published, peer-reviewed study. The 80-week results offer promising evidence, but questions about long-term safety and clinical use remain.

Table of Contents

  • How the 80-week retatrutide and Ozempic trial worked
  • A1C reduction and weight loss results
  • How triple-receptor therapy differs from GLP-1 treatment
  • Safety signals and clinical implications
  • Conclusion
  • Frequently asked questions

How the 80-Week Retatrutide and Ozempic Trial Worked

The TRANSCEND-T2D-2 trial was a randomized, open-label Phase 3 study involving 1,298 adults with type 2 diabetes. Participants had inadequate blood glucose control while taking metformin, with or without an SGLT2 inhibitor. Their average starting A1C was 8.3%, while average body weight was 225.8 pounds.

 

Researchers assigned participants to weekly retatrutide 9 mg, retatrutide 12 mg, or injectable semaglutide 2 mg, marketed as Ozempic. The groups followed a 2:2:1 randomization ratio, meaning more participants received retatrutide than Ozempic. Retatrutide treatment began at 2 mg, with doses increased every four weeks until participants reached their assigned targets.

The primary goal was to determine whether retatrutide 12 mg was at least as effective as Ozempic 2 mg at reducing A1C after 80 weeks. Researchers also examined additional outcomes, including weight loss and treatment-related side effects.

Importantly, the trial was open-label, meaning participants and investigators knew which medication was being administered. Although this design supports direct treatment comparisons, awareness of treatment assignments may influence certain reported outcomes.

The study is registered on ClinicalTrials.gov under NCT06260722. Notably, the comparison involved Ozempic 2 mg rather than every available semaglutide formulation or dose.

A1C Reduction and Weight Loss: What the 80-Week Data Show

According to Eli Lilly's October 2026 announcement, both retatrutide doses reduced A1C by an average of 2.2 percentage points. By comparison, Ozempic 2 mg produced an average reduction of 1.8 percentage points.

The difference of 0.4 percentage points suggests an additional glucose-lowering benefit with retatrutide. However, the statistical interpretation varied between treatment groups. Retatrutide 12 mg demonstrated statistically significant superiority under the trial's controlled testing procedure, while the 9 mg comparison showed nominal statistical significance.

Weight loss results revealed an even larger difference between treatments.

Participants receiving retatrutide 9 mg lost an average of 44.3 pounds, representing 19.5% of their starting weight. Meanwhile, those receiving 12 mg lost approximately 47.4 pounds, or 20.9%.

In comparison, participants receiving Ozempic 2 mg lost an average of 20.9 pounds, equivalent to 9.4% of their starting weight.

Therefore, both retatrutide groups achieved more than twice the percentage weight loss observed with Ozempic 2 mg.

These outcomes are particularly relevant because managing excess weight can improve insulin sensitivity and support broader diabetes treatment goals. Nevertheless, the results represent group averages rather than guaranteed individual responses.

Furthermore, Lilly reported these findings using an efficacy analysis that estimated outcomes while participants remained on assigned treatment without prolonged additional glucose-lowering medication. Consequently, results may differ from those observed in routine clinical practice.

How Triple-Receptor Therapy Differs From GLP-1 Treatment

What might explain the differences between retatrutide and semaglutide?

Both medications influence hormone pathways involved in appetite and blood glucose regulation. However, their mechanisms of action are different.

Ozempic contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. It helps stimulate insulin release when glucose levels are elevated, slows stomach emptying, and reduces appetite. These effects support improved blood glucose control and weight management.

Retatrutide works through three hormone receptors rather than one. It activates GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors.

GLP-1 and GIP contribute to insulin regulation and metabolic control. Meanwhile, glucagon receptor activity may increase energy expenditure, potentially contributing to additional weight loss.

This triple-receptor approach distinguishes retatrutide from existing GLP-1 therapies. For example, Mounjaro (tirzepatide) targets GIP and GLP-1 receptors but does not directly activate the glucagon receptor.

However, a broader mechanism does not automatically make a treatment superior across every clinical outcome. Although retatrutide demonstrated greater A1C reductions and weight loss in this study, the findings do not establish additional protection against cardiovascular events, kidney failure, or mortality.

Safety Signals and What Clinicians Should Watch

Greater treatment effectiveness must be considered alongside tolerability and safety.

Gastrointestinal symptoms were among the most frequently reported adverse events across treatment groups. Diarrhea occurred in 28.3% of participants receiving retatrutide 9 mg and 32.7% receiving 12 mg, compared with 26.4% taking Ozempic.

Similarly, nausea affected 21.2% and 23.8% of retatrutide recipients, compared with 21.3% in the Ozempic group. Vomiting occurred in 10.2%, 15.0%, and 13.2% of participants, respectively.

According to Lilly, most gastrointestinal events were mild to moderate and typically resolved during treatment.

Another finding involved dysesthesia, a condition that causes unusual or unpleasant skin sensations, including tingling, burning, or heightened sensitivity.

Dysesthesia occurred in 4.8% of participants taking retatrutide 9 mg and 6.5% receiving 12 mg. In contrast, 2.7% of Ozempic recipients reported the condition.

This signal deserves attention because people with diabetes may already experience nerve-related symptoms. However, these findings do not establish the underlying cause of dysesthesia or whether the symptoms involve the same processes as diabetic neuropathy.

Treatment discontinuation also differed between groups. Adverse events led to discontinuation in 4.8% of participants receiving retatrutide 9 mg and 7.9% receiving 12 mg, compared with 2.7% taking Ozempic.

Therefore, clinicians will need to consider whether greater metabolic improvements justify the potential increase in treatment burden for individual patients.

Importantly, Ozempic has established cardiovascular and kidney outcome evidence for certain patient populations. The TRANSCEND-T2D-2 results do not demonstrate that retatrutide provides equivalent or greater protection against these complications.

Until more complete evidence becomes available, treatment decisions should continue to follow established recommendations. Additional discussions of guideline-based diabetes prescribing and person-centered diabetes care can help clinicians weigh medication effectiveness against individual health needs, preferences, and treatment barriers.

Conclusion

These findings suggest that retatrutide's triple-receptor approach may provide greater A1C reductions and weight loss than Ozempic 2 mg in certain adults with type 2 diabetes.

However, the benefits must be balanced against gastrointestinal side effects, higher treatment discontinuation rates, and the reported dysesthesia signal.

Most importantly, retatrutide remains investigational and is not approved for routine clinical use as of November 2026. Full peer-reviewed findings and longer-term safety evidence will be essential before its place in diabetes treatment can be determined.

Frequently Asked Questions

  • Did retatrutide outperform Ozempic in the 80-week trial?
    Yes. Eli Lilly reported greater average A1C reductions and more than twice the percentage weight loss with both retatrutide doses compared with Ozempic 2 mg. However, the findings are currently based on company-reported topline results.
  • How much did retatrutide lower A1C compared with semaglutide?
    Retatrutide reduced A1C by an average of 2.2 percentage points, compared with 1.8 percentage points for Ozempic 2 mg. This represents an additional reduction of 0.4 percentage points.
  • What makes retatrutide different from Ozempic?
    Retatrutide activates three hormone receptors: GLP-1, GIP, and glucagon. Ozempic activates only the GLP-1 receptor. This difference may contribute to their distinct effects on glucose control and weight loss.
  • What were the main side effects reported in the trial?
    Gastrointestinal symptoms, including diarrhea, nausea, and vomiting, were common. Additionally, dysesthesia and treatment discontinuation due to adverse events occurred more frequently in the retatrutide groups.
  • Is retatrutide available for treating type 2 diabetes?
    No. Retatrutide remains an investigational medication as of November 2026. Patients should discuss currently approved diabetes treatments with their healthcare provider or seek guidance from a qualified professional through Healthcare.pro.

This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.